Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial
Most Cited Paper
in Heart Failure Treatment and Management
18 Months Post-Publication
Class of 2026
“Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial”
A research intelligence initiative by Pepkio
pri.pepkio.com
Topics
semaglutide · GLP-1 receptor agonist · Major adverse cardiovascular events · SELECT trial · Heart failure with preserved ejection fraction · Heart failure with reduced ejection fraction · atherosclerotic cardiovascular disease · Obesity · Cardiovascular mortality · Heart failure hospitalization · Myocardial infarction · Stroke · once-weekly subcutaneous administration · 2.4 mg dose · BMI 27 kg/m² or greater · composite heart failure outcome · All-cause mortality · New York Heart Association status · prespecified analysis · Double-blind randomized controlled trial
Share
Cite this ranking
Pepkio Research Index (PRI). Topics and Trends in Most Cited Heart Failure Treatment and Management Papers, Class of 2026. https://pri.pepkio.com/top-papers/heart-failure-treatment-and-management/2026. Accessed 2026-08-20. Methodology Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459